Protection by Neuroglobin Expression in Brain Pathologies

Eliana Baez1, Valentina Echeverria2, Ricardo Cabezas1, Marco Ávila-Rodríguez1, Luis Miguel Garcia-Segura3* and George E. Barreto1,4*

1 Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia,
2 Facultad de Ciencias de la Salud, Universidad San Sebastián, Concepción, Chile, 3 Instituto Cajal, CSIC, Madrid, Spain,
4 Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile

Astrocytes play an important role in physiological, metabolic, and structural functions, and when impaired, they can be involved in various pathologies including Alzheimer, focal ischemic stroke, and traumatic brain injury. These disorders involve an imbalance in the blood flow and nutrients such as glucose and lactate, leading to biochemical and molecular changes that cause neuronal damage, which is followed by loss of cognitive and motor functions. Previous studies have shown that astrocytes are more resilient than neurons during brain insults as a consequence of their more effective antioxidant systems, transporters, and enzymes, which made them less susceptible to excitotoxicity. In addition, astrocytes synthesize and release different protective molecules for neurons, including neuroglobin, a member of the globin family of proteins. After brain injury, neuroglobin expression is induced in astrocytes. Since neuroglobin promotes neuronal survival, its increased expression in astrocytes after brain injury may represent an endogenous neuroprotective mechanism. Here, we review the role of neuroglobin in the central nervous system, its relationship with different pathologies, and the role of different factors that regulate its expression in astrocytes.

Keywords: astrocytes, neuroglobin, mitochondria, neuroprotection, brain injury

INTRODUCTION

The brain has about 170 billion cells (1), which consume an average of 516 kcal of energy per day, representing 22% of total energy demand of an organism (2). This energy demand is required to carry out essential functions such as synaptic transmission, uptake and metabolism of neurotransmitters, and maintenance of ion gradients (3). For this reason, it is of pivotal importance to maintain optimal conditions of the intracellular environment targeting nerve cells needs. However, in diseases such as ischemic and traumatic brain injuries, an energy imbalance induced by the interruption of blood flow leads to metabolic stress, ionic disturbance, and activation of a complex cascade of biochemical and molecular events that can cause neuronal death (4). Moreover, there are other diseases such as hypoglycemia and diabetes, in which a misbalance in glucose levels can trigger brain damage (5, 6). In this context, traumatic brain injury has become a global public health problem, and it is the leading cause of death in individuals under 45 years of age and recurrent in young people, adolescents, and elders (7). Brain trauma induces cognitive and motor dysfunction (8). In a study reported by Quijano et al., cognitive abilities were assessed in subjects who suffered moderate head trauma and a control non-injured group. The results revealed significant differences in orientation, attention, memory, language, reading, and writing abilities (9). Despite the enormous efforts and
progress in research, treatment strategies for traumatic brain injury are still limited, and currently, there are no effective treatments against their consequences. It has been described that after injury, the first phase involves focal hematoma and diffuse edema that results in white matter damage. The second phase involves additional pathological cellular and molecular events such as the abnormal release of neurotransmitters, the generation of free radicals, Ca2+-signaling abnormalities, apoptotic factors activation, and mitochondrial dysfunction leading to neuronal damage, neuroinflammation, and brain dysfunction (10). Moreover, changes that occur in this second phase trigger the death of neurons and astrocytic reactivity. Therefore, it is necessary to search for therapeutic alternatives to prevent further neurological damage and restore CNS homeostasis upon injury.

Neurons are usually affected to a greater extent during injuries, since they have less antioxidant mechanisms than astrocytes being more affected by increased excitotoxicity than glial cells (11). Astrocytes have an active and critical role in the nervous system under normal and pathological conditions. During brain injury and neurodegenerative conditions, astrocytes participate in the removal of toxic molecules and promote neuronal survival throughout the release of trophic factors and antioxidant molecules (12). For example, astrocytes produce various antioxidant molecules, such as glutathione transferase (GST), superoxide synthase (SOD), and catalase, providing further antioxidant protection to neurons (13). Also, astrocytes integrate the blood–brain barrier (BBB) (13, 14), thus providing active support in the formation of neural connections and brain activity (15). These cells are key regulators of neuronal energy by providing them with lactate (16–18). For all these reasons, astrocytes are vital to restore brain function after injury. In different neurodegenerative conditions such as ischemia–reperfusion injury, a key role is played by mitochondria in the generation of reactive oxygen species (ROS), dysfunctional energy metabolism, and mitochondria-induced apoptosis (19). Likewise, the disruption of synaptic regulation by astrogliosis seems to play an important role in neurodegeneration and brain damage (20).

It is considered that a transient or permanent impairment of astrocytic functions may negatively impact neurons during pathological conditions. For this reason, it is important to expand the knowledge about the neuroprotective mechanisms mediated by astrocytes during brain injury to find alternatives to prevent altered responses affecting neuroprotection and recovery (21). In this context, neuroglobin (Ngb), a protein expressed astrocytes and neurons, of the central nervous system (CNS) and the peripheral nervous system (PNS) (22, 23) has often been linked to neuroprotection in different neuropathological conditions (24, 25) through antioxidant and antiapoptotic mechanisms (26, 27). The expression of Ngb is induced in human astrocytes during brain injury, possibly as a neuroprotective mechanism (28). Interestingly, Ngb is expressed in astrocytes and neurons of whales and seals as a mechanism to withstand long periods of hypoxia (29). However, more research is needed to completely address the importance of Ngb protective mechanisms and its relationship with astrocyte functions. In the present review article, we explore the role of Ngb in the CNS, focusing on astrocytes and its relationship with different pathologies.

### ASTROCYTES AND BRAIN PATHOLOGIES

Astrocytes are responsible for glucose uptake and release of lactate to neurons (16, 17, 30), which are involved in memory and cognition, glutamate recycling, and synthesis of antioxidant glutathione (31). Furthermore, astrocytes have a unique cellular structure that allows them to detect any change in the environment and dynamically respond to extracellular changes or metabolic requirements, providing sources of energy from the glucose taken from blood flow (32) or from energy reserves such as glycogen (33). In addition to glutathione, astrocytes have a special antioxidant system that includes glutathione peroxidase, heme oxygenase I, and catalase, which are able to detoxify ROS in the brain (32, 34). Astrocytes are also considered polyfunctional cells because they also contribute to the elimination of glutamate (Glu), the major excitatory neurotransmitter in the CNS (35). Moreover, Bergmann glia from the cerebellum express the EAAT1 and EAAT2 transporters (36). In this respect, the EAAT2 (GLT1) is responsible for 90% of glutamate uptake through the astrocyte endfeet that make direct contact with the synapses (37). However, this mechanism of Glu uptake and transport becomes affected during brain pathologies, and the increased levels of Glu in the extracellular space might induce excitotoxicity and the severity of brain injury (38, 39). Other astrocytic functions include the remodeling of the blood brain barrier (14) and production of growth factors (18, 40, 41), which in turn promote cell repair during episodes of injury. Faced with an insult or injury, astrocytes adopt a reactive metabolic phenotype (16, 17, 42–44). This phenotype has a beneficial effect on the preservation of neural tissue and in the restriction of moderate focal inflammation (17, 45, 46). However, when this response is maintained and generalized, it can become counterproductive because astrocytic efforts are redirected toward defensive and repair tasks at the expense of providing adequate metabolic support to neurons and also by blocking axonal regeneration (47). Despite this controversial harmful role of reactive astrocytes, a recent study indicated that astrocyte scar formation might help axon regeneration by augmenting multiple axon-growth-supporting molecules (48), demonstrating that inhibiting glial scar might reduce axon regrowth and worsen CNS damage.

According to Sofroniew (49–51), reactive astrogliosis covers some key characteristics: (1) molecular, cellular, and functional changes in astrocytes related to the severity of injury in the CNS; (2) changes are regulated by specific context of molecules via inter- and intracellular signaling; and (3) astrogliosis can exert an alteration in normal astrocytic activities, which in turn can lead to positive or harmful effects in surrounding cells. Additionally, astrocyte gap junctions can remain open after brain injury (52), allowing the entrance of pro-apoptotic factors and immune cells that exacerbate cellular injury (53).

Astrocytes, as other CNS cells, are affected by decreased levels of ATP. This decrease in ATP levels is associated with two fundamental aspects: (i) decreased cerebral blood flow to the range of 100 g−1 (5–8.5 ml min−1), which leads to irreversible tissue damage by the small amount of glucose and oxygen available (8), and (ii) increased intracellular calcium that leads to damaging calcium levels in mitochondria (54). These facts suggest the
importance of astrocytic protection as a potential therapeutic target for neuroprotection and preservation of CNS functions following injury.

Mitochondrial Function and Dysfunction in Astrocytes
Mitochondria are essential organelles to sustain life and the physiological function of cells under normal conditions by maintaining energy balance through substrate oxidation, modulation of calcium levels, and redox balance (13, 30, 55). However, these organelles are also the main target of oxidative stress (30) by an imbalance between the production of oxidative molecules, such as hydrogen peroxide (H₂O₂), superoxide radical (O₂⁻), and the hydroxyl radical (OH), and the ability of the cell to defend against these radicals (56). Because there is a close relationship between mitochondrial dysfunction and brain injury, mitochondrial protection has become a main therapeutic strategy for treating multiple neurodegenerative diseases, such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis, among others (13, 30, 40, 57–59).

As reviewed by Kubik and Philbert (60), from a total of 12,614 mitochondrial investigations in cells of the nervous system, only 1,214 were directed to astrocytic mitochondria. This fact overshadows that mitochondria in astrocytes provide the metabolic substrates necessary for neural function and are essential to maintain the energetic balance of the brain and the production of antioxidants (61, 62). For example, according to Voloboueva et al. (63), the inhibition of mitochondria during glucose deprivation conditions induces functional changes in astrocytes related to a decrease in ATP levels, depolarization of the plasma membrane, and reduced glutamate uptake, without a significant loss of their viability. Therefore, this evidence strongly suggests that the damage to the astrocytic mitochondrial function may be the start of brain lesions and neuronal death (61).

Studies in animal models of PD showed that the administration of 1 and 10 µg of either vascular endothelial growth factor (VEGF) or glial-derived neurotrophic factor (GDNF) increased the expression of mitochondrial genes (64), suggesting that these growth factors may have a role in mitochondrial protection. Similarly, in vitro administration of platelet-derived growth factor BB (PDGF-BB) preserved mitochondrial function in astrocytes treated with rotenone (40). Furthermore, another study reported that the transmembrane protein TrkB (a receptor for BDNF) was co-localized with mitochondria in astrocytes (63), suggesting that astrocytes’ mitochondria have the potential to directly interact with neurotrophic factors and other protective proteins such as Ngb (65, 66). Finally, other substances studied in mitochondrial protection are CoQ10 (Coenzyme Q10) and conditioned medium from mesenchymal stem cells (67–69). CoQ10 is a ubiquinone with multiple functions such as decreasing the production of ROS, stabilizing mitochondrial membrane potential, improving mitochondrial respiration, inhibiting mitochondria-mediated pathway of cell death, and activating the mitochondrial biogenesis (69). On the other hand, conditioned medium from mesenchymal stem cells has been shown as a protective substance, which contains proangiogenic and antiapoptotic factors, immunomodulators, antioxidants, and neuronal differentiation factors among others, that improve the mitochondrial protection during injuries (68). However, further studies are necessary in order to find new methodologies for the protection of astrocytic mitochondria.

NEUROGLOBIN IN BRAIN PATHOLOGIES
Oxygen depletion is one of the more detrimental conditions for the CNS, inducing irreversible damage and as a result loss of cognitive functions. Oxygen depletion is underlying several CNS diseases such as ischemia or TBI.

As stated above, aquatic mammals such as whales and seals (29) withstand conditions of severe hypoxia without damage; they are unique models to investigate neuroprotective mechanisms. The comparison of Ngb protein sequence between terrestrial and aquatic mammals revealed minor differences in its sequence of only two or three amino acids, which did not give rise to confer functional differences between both groups. However, Ngb mRNA expression levels were 4–15 times higher in the brain of seals and whales than in those from terrestrial mammals, suggesting that higher Ngb levels in aquatic mammals can be a neuroprotective mechanism against brain hypoxia and ROS production (70). Similarly, in a behavioral study in transgenic mice overexpressing Ngb under normoxia and hypoxia, it was shown that Ngb promotes survival in vivo and may play an important role in countering the adverse effects of a hypoxic ischemic stroke. No significant behavioral differences were detected between control and Ngb overexpressing mice at 3 months of age, but transgenic mice showed a superior behavioral performance than control mice at 1 year of age (71).

Traumatic brain injury is another major pathology of the brain, which affects world population. Basic features include bleeding, cell death, increased production of β-amyloid, basic fibroblast growth factor (FGF-2), and increased expression of Ngb that remains upregulated until the sixth day post-injury (72). In this respect, other studies have demonstrated an increased expression of Ngb with stroke, hypoxia, and ischemia (73, 74). In an experimental model of TBI, overexpression of Ngb correlated with a significant reduction in sensorimotor deficits compared with a control group that did not overexpressed Ngb. The immunohistochemical analysis of injured cortex and hippocampus revealed that Ngb is mainly expressed in neurons and glial cells (75).

Human studies have correlated the genetic polymorphisms of the Ngb with susceptibility to neurodegeneration. One of these studies showed that decreased expression of Ngb in the elderly is associated with an increased risk of AD (78). In a preclinical study using transgenic AD mice, it was found that intracerebroventricular injection of Ngb decreased the formation of Aβ peptides, and the mitochondrial dysfunction, apoptosis, and neuronal death in the AD brains. In addition, other studies suggested that the neuroprotective effects of Ngb involved the inhibition of caspase-3 and 9, the activation of the PI3K/Akt pathway (77), and the removal of proteins aggregates (77). Finally, other study has demonstrated that Ngb is related to the neurotoxic effect produced by CNS 1-bromopropane (1-BP), a volatile organic compound implicated in damage...
to both the ozone layer of the atmosphere and the CNS. This compound is used as a cleaning agent for metal, electronics, and optical instruments, as well as a substrate for the synthesis of pharmaceuticals and insecticides (79). The frequent use of this compound may cause health problems in mammals. For example, a previous study showed that exposure to 1-BP resulted in cognitive deficits and increased levels of 4-HNE and MDA modified proteins in rats (80). Also, rats exposed to 1-BP showed elongated astrocytic processes, a decreased number of oligodendrocytes, suggesting possible negative effects on myelination and degeneration of granular and Purkinje cells in the cerebellum (81). Similarly, a previous study showed that occupational exposure to 1-BP resulted in CNS adverse effects and peripheral neuropathy (82). Some evidence suggests that Ngb dysfunction may be involved with the toxic effects of 1-BP on CNS. For example, 1-BP correlated in a dose-dependent manner with a decrease in Ngb, cognitive dysfunction in rats, and a significant loss of neurons in layer V of the prelimbic cortex. These results suggest that the decreased expression of Ngb probably plays an important role in CNS neurotoxicity induced by 1-BP (83).

It is important to highlight that the presence of Ngb in vivo or in vitro depends on specific astrocytes (84) and the brain region affected. For example, in one study, Ngb-positive astrocytes were mostly found in the rhinencephalon region severely damaged in terms of hemorrhage (85, 86). However, Ngb was not detected in astrocytes from healthy mouse brains, suggesting that Ngb may have cytoprotective properties with the potential to be a therapeutic agent for intervention. However, the potential neuroprotective effect of Ngb in astrocytes (28) during ischemia (84) has neither been characterized nor the role of Ngb in neurogenesis and glial scar (28). In addition, whether Ngb is secreted by astrocytes as a neuroprotective agent has not been explored, and it requires further investigations.

NEUROPROTECTIVE POTENTIAL OF NEUROGLOBIN

Until recently, hemoglobin (Hb) was the most studied member of the globin family of proteins because of its oxygen-binding affinity in blood. Nevertheless, recent studies have revealed expression of other globin proteins in erythrocytes of vertebrates, including myoglobin (Mb), cytoglobin (CYGB), globin E (GbE), globin Y (GbY), and Ngb (87). Ngb is a 17-kDa monomeric protein, which shows a classic folded structure adapted to hold the heme-hexa-Fe-type HisF8 HisE7 in both the ferric and ferrous forms (26). According to homology studies, it was found that Ngb sequence is highly conserved between species, accounting for almost 76% of sequence conservation between humans and amphibians (88). Ngb is not only expressed in the nervous system (22) but also in the eyes, intestine, and ovary; however, no expression has been detected in kidney liver, heart, and skeletal muscle (89). In the brain, Ngb has been found in different regions including the cortex, thalamus, cerebellum, hippocampus, and hypothalamus (90). These areas are important in the processing of sensations, memory, and learning, and are often affected in hypoxic and ischemic insult or traumatic injuries.

Ngb, with its molecular properties, has been characterized as a protein responsible for O2 transport and scavenging of ROS and as O2-sensor and oxygen transporter (91). These functions suggest that the presence of Ngb is a key factor to brain homeostasis. At present, there are several studies addressing the role of Ngb in different pathologies such as focal ischemia and hypoxic–ischemic injuries (92–95). These studies suggest that Ngb serves as a sensor to hypoxic stress and has a protective effect. For example, Tiso et al. (96) reported that a nitrite reductase activity of Ngb inhibited mitochondrial respiration in presence of nitrite in vitro and suppressed oxygen consumption and ROS production. Current studies have shown a direct functional relationship between mitochondrial integrity and Ngb in vivo (74). For example, Ngb is associated with reduced oxidative damage induced by either reactive nitrogen species (RNS) or ROS (97). Moreover, Ngb structure was found to be extremely stable, in which its holoprotein was able to support temperatures exceeding 100°C and low pH values of up to 2.0 before denaturation (98). Finally, this protein may be involved in enhancing G-protein signal transduction by inhibiting the dissociation of guanosine diphosphate from the G-α subunit (73, 99, 100) and therefore involved in cell signaling processes (66).

Initially, Ngb was considered to be exclusively a cytoplasmic protein (101), but recent confocal microscopy studies have shown that it is also located in mitochondria and nucleus (102, 103). In this respect, it was shown that Ngb is associated with microdomains of lipid rafts and α-subunits of heterotrimeric protein G and becomes activated during oxidative stress, undergoing structural changes that lead to neuroprotection (103). On the other hand, the mitochondrial expression of Ngb becomes increased after oxygen-glucose deprivation (OGD) in primary cultures of mouse cortical neurons (104, 105). Furthermore, mitochondrial Ngb has interactions with cytochrome c and the voltage-dependent anion channel (VDAC), suggesting the importance of Ngb in mitochondrial function and neuroprotection (73, 106, 107). Additionally, it has been shown the influence of thyroid hormones on Ngb expression (97, 108). In one of these studies, the authors evaluated Ngb expression in different areas of the rat brain after T3 (100 L/100 g) administration. The authors found that T3 increased Ngb expression in the hippocampus and cerebellum; however, in cerebellum, Ngb expression was only detected at 120 min, 6 h, 12 h, and 24 h after T3 injection (97).

Other studies have shown that Ngb promoter is regulated by the transcription factors NFκB, Sp1, and CREB (109), the hypoxia-inducible factor 1-α (HIF-1α), erythropoietin (EPO), and the VEGF (84, 110). In this respect, it was observed that VEGF2 increased the expression of Ngb by stimulating the Flk1 receptor, which in turn induced the expression of HIF-α (111).

The mechanisms of neuroprotection by Ngb have not been completely elucidated. Various stimuli can affect the expression of Ngb in different tissues, including the CNS. For example, in the cardiac tissue, which is also affected by ischemia, oxidative stress, and reperfusion, Ngb has been involved in the protection against cardiac hypertrophy induced by oxidation in cardiomyocytes, preventing them from cell death by ROS and therefore can be a clinical candidate for the treatment of heart diseases (112). On the other hand, it has been shown that cochlear oxidative stress
is the main cause of sensorineural hearing loss and for which so far there is no treatment. In this aspect, Ngb is highly expressed in the cochlear nuclei and the superior olivary complex (SOC). Moreover, it was reported that Ngb is colocalized with the antioxidant neuronal protein nitric oxide synthase (NOS) in the SOC, suggesting the importance of Ngb in oxygen homeostasis and energetic metabolism in the auditory nervous system (113) (see Table 1). Ngb has been also involved in calcium homeostasis (27), ATP storage, inhibition of actin assembly, and response against increased hydrogen peroxide ion levels. This evidence suggests that Ngb is also involved in the maintenance of the integrity of the cytoskeleton, cell viability, neuroprotection, and glutamate removal (114).

Recent studies have used different drugs to increase Ngb expression in neurons as a therapeutic neuroprotective agent in traumatic brain injury. Among the drugs studied are deferoxamine, an iron chelator, valproic acid, and cinnamic acid (121). Further in vivo studies are needed in order to determine both the induction levels of Ngb by these drugs and also if they have adverse effects in the sensorimotor or cognitive recovery after traumatic brain injury or brain ischemic injury.

### Antioxidant Effect

Ngb has very little affinity for oxygen, and the oxygenated species formed with Ngb are unstable; thus, it does not provide a stable source of oxygen, due to the low concentration of Ngb in neurons (128). In fact, it is recognized that one of the roles of Ngb is basically its affinity for NO (26, 129), and this action can be related to the clearance of this gaseous ligand. Moreover, Ngb has been shown to act as a ROS and RNS scavenger in different models

### TABLE 1 | Description of the fundamental aspects and biological effects of neuroglobin.

| Aspect | Description | Reference |
|--------|-------------|-----------|
| **Expression of neuroglobin**<br>in the CNS | Cerebellum and hippocampus | (97) |
| | Cortex, thalamus, cerebellum, hippocampus, and hypothalamus | (90) |
| **Non-neuronal cells expressing neuroglobin** | Cardiomyocytes | (112) |
| | Spinal ganglion cells and the superior olivary complex | Stem auditory | (113) |
| | Retina cells | (115) |
| **Antioxidant role of neuroglobin** | Regular removal of nitric oxide | (26, 116) |
| | Decrease the damage induced by reactive nitrogen species | (97) |
| **Antiapoptotic role of neuroglobin** | Survival in nerve cells overexpressing neuroglobin | (24) |
| | Decrease apoptosome formation | (25) |
| | Cytochrome c reduction | (24) |
| | Decreased levels of calcium – upholding levels of ATP – mitochondrial membrane potential in cultured neuronal cells | (27-117) |
| | Modulation of metals such as iron, copper, and zinc in cultured neuronal cells | (117) |
| | Increased ATP reservoirs in cultured human neuronal cells | (114) |
| **Signaling pathways involving neuroglobin** | Inhibits the dissociation of guanosine diphosphate from protein G-α | (99, 100) |
| | It binds to the subunit Gβγ that activates PI3K and Akt in cultured human neuronal cells | (114) |
| | Inhibits production of IP3 | (118, 119) |
| | Inhibits actin assembly-mediated Rac-1 in neurons | (123) |
| **Factors that mediate expression of neuroglobin** | HIF-1α | (110) |
| | NFκB-SP1-CREB | (109) |
| | VEGF | (84, 111) |
| | EPO | (84) |
| **Drugs that increase neuroglobin expression in neurons** | Deferoxamine-valproic acid-cinnamic acid in HN33 (mouse hippocampal neuron x N18TG2 neuroblastoma) cells | (121) |
| **Neuroglobin expression in astrocytes** | Neuroglobin after a subacute and chronic traumatic brain injury | (28) |
| | Neuroglobin in microglia and astrocytes after traumatic brain injury | (84, 122) |
| | Neuroglobin astrocytes through estrogen receptor ERβ | (22) |
| | Co-localization of neuroglobin with GFAP in human brain after a stroke | (20) |
| | Neuroglobin protection is mediated via Raf/MEK/ERK through 14-3-3ε | (123) |
| | Neuroglobin expression is dependent on the activation of estrogen receptor beta; tibolone induces the upregulation of Ngb | (65) |
| | Testosterone upregulates Ngb expression in glucose deprived cells | (124) |
| **Related pathologies involving neuroglobin** | Cerebral hypoxia | (70, 71, 125, 126) |
| | Focal cerebral ischemia | (127) |
| | Alzheimer | (76) |
| | Injury in the cerebral cortex | (72) |
| | Stroke | (73) |
| | Traumatic brain injury | (74) |
| | Removal of proteins capable of forming aggregates deleterious | (78) |
| | Neurotoxic effect of 1-bromopropane | (83) |
(84, 112, 122), although its antioxidant activity is lower than that of N-acetyl cysteine, glutathione, and vitamin C (115). Finally, Ngb has interactions with many antioxidant-related proteins such as Cyt c, Thio, AIF, Prdx3, 4, and 6, Thor1, and Dj1, among others. However, further research is needed in order to address the relevance of the antioxidant effects of Ngb in CNS diseases.

**Antiapoptotic Effect of Ngb**

The process of apoptosis is complex, and few have investigated the action of Ngb. However, some studies used computational modeling to determine the mechanism of Ngb in cell death. For example, data obtained using computational modeling suggest that Ngb reduces the formation of the apoptosome by a redox reaction with cytochrome c (24), causing the blocking of initiator pro-caspase 9 activation and thus significantly blocking the triggering of apoptosis. In the same study, the authors simulated the interaction between Ngb and cytochrome c and validated their results using an *in vitro* approach. The authors found a very rapid reaction between reduced (ferrous) neuroglobin and oxidized (ferric) cytochrome c (24), suggesting that Ngb might affect the initiation of apoptosis by interacting with cytochrome c. Interestingly, under normal conditions, these molecules do not interact with each other, but under stress, Ngb prevents cytochrome c release from mitochondria, thus protecting the cell from apoptosis (115). In this respect, it was reported that after reducing cytochrome c, Ngb, in the ferric form, binds to two receptors coupled to G protein subunits (GPCR). This fact is interesting, as the G-α subunit can cause an inhibition in the production of IP3 (inosine triphosphate) and reduce cytosolic calcium release (118, 119). On the other hand, Ngb binds to the Gβγ subunit, activating PI3K and Akt and thus promoting cell viability (114). Also, as mentioned before, Ngb inhibits Rac-1, Pak1 kinase, and actin assembly, preventing cytoskeletal rearrangement and avoiding the initiation of death signaling (120). Moreover, Ngb expression has been found to be higher in metabolically active cells, such as neurons and retinal cells, which have some features in common such as high cytosolic calcium levels, which can trigger apoptosis (115). This aspect has already been validated experimentally, showing that increased Ngb expression is directly linked to calcium homeostasis and maintenance of both mitochondrial membrane potential and ATP levels (27). Ngb may be also important in the modulation of metallic ions such as Fe, Cu, and Zn, which are increased in neurons under hypoxic conditions. These ions can induce inflammation, mitochondrial damage, ROS production, and the release of neurotransmitters, leading to neuronal death excitotoxicity (117). All these findings support the role of Ngb in apoptotic regulation, a subject that merits further research.

**NEUROGLOBIN EXPRESSION IN ASTROCYTES**

The expression of Ngb is evident in neurons and the protective role of Ngb in neuronal cells has been well documented; however, the function of Ngb in astrocytes is less well studied (84). In 2000, a study reinforced the expression of Ngb mRNA in spinal cord funicles, hippocampal alveus, and cerebellar medulla of rodents (101). Until recently, only few studies have reported the expression and function of Ngb in astrocytes (28, 84, 122, 130). Previously, in 2005, a study reported that Ngb mRNA was detected in primary cultures of cortical astrocytes and transfection of these astrocytes with anti-sense for Ngb led to a 2.5-fold increase in apoptotic cells when compared to controls, suggesting a possible protective role of Ngb expression in astrocytes against insult (131).

Consistently, Avivi et al. reported that the subterranean mole rat (Spalax) expresses Ngb in neurons and astrocytes isolated from the corpus callosum (125). More recently, Lechauev et al. reported that Ngb was detected in astrocytes processes optic nerve under physiological conditions *in vivo* (132). Indeed, it is important to mention that Ngb expression has been also observed in astrocytes under pathological conditions (e.g., reactive astrocytes). For example, the expression of Ngb was found upregulated in reactive astrocytes located in the proximity of a penetrating cortical injury *in vivo* (22, 133), in Müller cells during reactive gliosis (132) or located in regions associated with the most severe pathology and the astroglial scar in murine models (134). Moreover, Ngb was also detected in astrocytic tumors such as rat astrocytoma cells (C6) and human astrocytoma cells (U251) (135, 136), thus confirming the existence of Ngb in tumoral cell lines.

A previous study evaluated Ngb expression in astrocytes after brain trauma and reported that Ngb expression is present in subacute and chronic injuries but not acute trauma (28). Moreover, in other studies, it was found that Ngb is expressed in microglia and astrocytes specifically during conditions such as traumatic brain injury (84, 122) and that estradiol regulates the expression of Ngb in astrocytes (66) through the estrogen receptor β (ERβ) (22), while ERα is involved in the regulation of Ngb in neurons (137). Interestingly, tibolone, a synthetic hormone with estrogenic, prostogenic, and androgenic actions, has also been reported to induce Ngb expression in astrocytic-like cells *in vitro* under glucose deprivation (65) (Figure 1). This expression was dependent on the activation of ERβ. Moreover, inhibition of Ngb by siRNA significantly affected the protective effects of tibolone in glucose-deprived cells, suggesting that its actions might be mediated by ERβ and Ngb upregulation (65). Similarly, testosterone also induced the expression of Ngb in astrocytes subjected to glucose deprivation, indicating that estrogenic and androgenic compounds might play a protective role *via* induction of Ngb (124). Furthermore, a previous report (130) showed co-localization of Ngb and GFAP in glia from human brains after stroke (28). It has been postulated that neuroprotection by Ngb in astrocytes is mediated by Raf/MEK/ERK pathway through 14-3-3r, which has the ability to bind to multiple signaling proteins as kinases, phosphatases, or transmembrane receptors (123). Controversially, Ngb has not been detected in astrocytes by conventional immunohistochemistry or fluorescent immunostaining in normal mice brains (134). Indeed, a strong correlation between the cellular expression of Ngb and the neuronal marker NeuN, but not the astroglial marker GFAP, has been found (130). These results indicate that is debatable whether Ngb is expressed in astrocytes and others glial cells under non-pathological conditions (84). Nevertheless, Ngb is detected in...
endogenous mechanisms of neuroprotection. Ngb is upregulated and its enhanced expression after brain injury probably reflects a potential target to decrease neural damage, antioxidative and antiapoptotic properties acting on mitochondrial and cytosolic mechanism of pathology. Therefore, Ngb can be considered as a potential target to decrease neural damage, and its enhanced expression after brain injury probably reflects endogenous mechanisms of neuroprotection. Ngb is upregulated by pharmacological compounds, such as estrogenic molecules. Overexpressing Ngb by gene therapy or its pharmacological induction may represent a potential therapeutic approach for the treatment of traumatic brain injury.

CONCLUSION AND PERSPECTIVES

The studies reviewed here show that Ngb is a molecule with antioxidative and antiapoptotic properties acting on mitochondrial and cytosolic mechanism of pathology. Therefore, Ngb can be considered as a potential target to decrease neural damage, and its enhanced expression after brain injury probably reflects endogenous mechanisms of neuroprotection. Ngb is upregulated by pharmacological compounds, such as estrogenic molecules. Overexpressing Ngb by gene therapy or its pharmacological induction may represent a potential therapeutic approach for the treatment of traumatic brain injury.

AUTHOR CONTRIBUTIONS

EB, GEB, VE, and LG-S wrote the manuscript; RC revised the manuscript; and MA-R provided the figure.

ACKNOWLEDGMENTS

GB’s work is supported by Pontificia Universidad Javeriana.

REFERENCES

1. Azevedo FAC, Carvalho LRB, Grinberg LT, Farfel JM, Ferretti REL, Leite REP, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol (2009) 513:532–41. doi:10.1002/cne.21974
2. Carmody RN, Waangham RW. The energetic significance of cooking. J Hum Evol (2009) 57:379–91. doi:10.1016/j.jhevol.2009.02.011
3. Magistretti P, Ransom B. Astrocytes. In: Davis KL, Charney DS, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: The Fifth Generation of Progress. American College of Neuropsychopharmacology (2002).
4. Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab (2004) 24:133–50. doi:10.1097/01.WCB.0000111614.19196.04
5. Bree AJ, Puente EC, Daphna-Iken D, Fisher SJ. Diabetes increases brain damage caused by severe hypoglycemia. Am J Physiol Endocrinol Metab (2009) 297:E194–201. doi:10.1152/ajpendo.91041.2008
6. Zhou D, Qian J, Liu CX, Chang H, Sun RP. Repetitive and profound insulin-induced hypoglycemia results in brain damage in newborn rats: an approach to establish an animal model of brain injury induced by neonatal hypoglycemia. Eur J Pediatr (2008) 167:1169–74. doi:10.1007/s00431-007-0653-2
7. Bruns J, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia (2003) 44:2–10. doi:10.1046/j.1528-1157.44.s10.3.x
8. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth (2007) 99:4–9. doi:10.1093/bja/aem131
9. Quijano MC, Arango JC, Cuervo MT, Aponte M. Neuropsicología del trauma craneoencefálico en Cali, Colombia. Rev Cienc Salud (2012) 10:21–31.
10. Maas AIR, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol (2008) 7:728–41. doi:10.1016/S1474-4422(08)70164-9
11. Swanson RA, Ying W, Kauppinen TM. Astrocyte influences on ischemic neuronal death. Curr Med Res (2004) 4:193–205. doi:10.2174/156852404479185
12. Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson’s disease. Neurotherapeutics (2010) 7:413–23. doi:10.1016/j.nurt.2010.07.001
13. Cabezas R, Avila M, Gonzalez J, El-Bacha RS, Barz E, Garcia-Segura LM, et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease. Front Cell Neurosci (2014) 8:211. doi:10.3389/fncel.2014.00211
14. Posada-Duque RA, Barreto GE, Cardona-Gomez GP. Protection after stroke: cellular effectors of neurovascular unit integrity. Front Cell Neurosci (2014) 8:231. doi:10.3389/fncel.2014.00231
15. Nedergaard M, Ransoms B, Goldman SA. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci (2003) 26:523–30. doi:10.1016/S0166-2236(03)00076-2
16. Barreto G, Gonzalez J, Torres Y, Morales L. Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. Neurosci Res (2011) 71:107–13. doi:10.1016/j.neures.2011.06.004
17. Barreto G, White RE, Ouyang Y, Xu L, Giffard RG. Astrocytes: targets for neuroprotection in stroke. Cent Nerv Syst Agents Med Chem (2011) 11:164–73. doi:10.2174/187152411796011303
18. Cabezas R, Avila-Rodriguez M, Vega-Vela NE, Echeverria V, Gonzalez J, Hidalgo OA, et al. Growth factors and astrocytes metabolism: possible roles for platelet derived growth factor. Med Chem (2016) 12:204–10. doi:10.2174/157340641166151019120444
19. Hu Y, Deng H, Xu S, Zhang J. MicroRNAs regulate mitochondrial function in cerebral ischemia-reperfusion injury. Int J Mol Sci (2015) 16:24895–917. doi:10.3390/ijms161024895
20. Maragakis NJ, Rothstein JD. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol (2006) 2:679–89. doi:10.1038/ncpneuro0355
Baez et al. Astrocytes and Neuroglobin

22. De Marinis E, Fiocchetti M, Acconcia F, Ascenzi P, Marino M. Neuroglobin
23. Bélanger M, Magistretti PJ. The role of astroglia in neuroprotection.
24. Raychaudhuri S, Skommer J, Henty K, Birch N, Brittain T. Neuroglobin
25. Dringen R, Hirrlinger J. Glutathione pathways in the brain.
26. Cabezas R, El-Bachá R, González J, Barreto G. Mitochondrial functions in
27. Chen X, Liu Y, Zhang L, Zhu P, Zhu H, Yang Y, et al. Long-term neuroglobin
28. Chen Y, Swanson RA. Astrocytes and brain injury.
29. Cabezas R, Avila MF, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
30. Zou J, Wang Y-X, Dou F-F, Lü H-Z, Ma Z-W, Lu P-H, et al. Glutamine
31. Lee M-C, Yamasu R, Ehlers MD. Metaplasticity at single glutamatergic syn-
32. Baez et al.
33. Iglesias J, Morales L, Barreto GE. Metabolic and inflammatory adaptation of
34. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, et al. Coordinate
35. Lee M-C, Yamasu R, Ehlers MD. Metaplasticity at single glutamatergic syn-
36. Medina-Ceja L, Guerrero-cazares H, Canales-aguirre A, Morales L. Neuroprotective
37. Jonker C, Klomp CM, Dullaart RP, Van der Heyde JC. The role of reactive
38. Barreto GE, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
39. Zou J, Wang Y-X, Dou F-F, Lü H-Z, Ma Z-W, Lu P-H, et al. Glutamine
40. Cabezas R, Avila MF, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
41. Chen Y, Swanson RA. Astrocytes and brain injury.
42. Barreto GE, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
43. Barreto GE, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
44. Iglesias J, Morales L, Barreto GE. Metabolic and inflammatory adaptation of
45. Myer DJ, Gurkoff GG, Lee SM, Hovda DA, Sofroniev MV. Essential pro-
46. Sofroniev MV, Vinters HV. Astrocytes: biology and pathology. Acta
47. Steele ML, Robinson SR. Reactive astrocytes give neurons less support:
48. Anderson MA, Burda JE, Ren Y, Ao Y, O’Shea TM, Kawaguchi R, et al. Astrocyte
49. Medina-Ceja L, Guerrero-cazares H, Canales-aguirre A, Morales L. Neuroprotective
50. Lee M-C, Yamasu R, Ehlers MD. Metaplasticity at single glutamatergic syn-
51. Iglesias J, Morales L, Barreto GE. Metabolic and inflammatory adaptation of
52. Bélinger M, Magistretti PJ. The role of astroglia in neuroprotection.
53. Lin JH, Weigel H, Cotrina ML, Liu S, Bueno E, Hansen AJ, et al. Gap-junction-mediated propagation and amplification of cell injury. Nat
54. Prins M, Greco T, Alexander D, Giza CC. The pathophysiology of traumatic brain
55. Jurado-Coronel JC, Avila-Rodriguez M, Cadenas F, Gonzalez J, Moran VE, Barreto GE. Targeting the nicotinic acetylcholine receptors (nAChRs) in
56. Medina-Ceja L, Guerrero-cazares H, Canales-aguirre A, Morales-Villagrán M, Aferia-Velasco A. Características estructurales y funcionales de los trans-
57. Avila Rodriguez M, Garcia-Segura LM, Cabezas R, Torrente D, Cadenas F, Gonzalez J, et al. 17beta-estradiol – a new modulator of neuroglobin levels in neurons: role in neuroprotection against H(2)O(2)-induced toxicity. Neurosignals (2010) 18:223–35. doi:10.1159/000323906
58. Kubik LL, Philbert MA. The role of astrocyte mitochondria in differential
59. Sofroniev MV, Vinters HV. Astrocytes: biology and pathology. Acta
60. Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson’s disease: genes, environment and mitochondria. Parkinsonism Relat Disord (2006) 12:1383–94. doi:10.1016/j.parkreldis.2006.05.005
61. Vartainen A, Tarkakoski J, Lonnqvist E, Hynynen S, Nemes S. Neuroglobin decreases brain hypoxia/reoxygenation-induced apoptosis in primary cultures of astrocytes. Neurochem Res (2010) 35:1323–32. doi:10.1007/s11064-010-0282-0
62. Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson’s disease: genes, environment and mitochondria. Parkinsonism Relat Disord (2006) 12:1383–94. doi:10.1016/j.parkreldis.2006.05.005
63. Voloboueva LA, Suh SW, Swanson RA, Giffard RG. Inhibition of mitochondrial
64. Yue X, Hariri DJ, Caballero B, Zhang S, Bartlett MJ, Kaut O, et al. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in precinematic in vivo models of Parkinson’s disease. Neuroscience (2014) 258:383–400. doi:10.1016/j.neuroscience.2013.11.038
65. Avila-Rodriguez M, Garcia-Segura LM, Hidalgo-Lanussa O, Baez E, Gonzalez J, Barreto GE. Tibolone protects astrocytic cells from glucose deprivation through a mechanism involving estrogen receptor beta and growth factor signaling. J Neurotrauma (2012) 29:415–27. doi:10.1089/neuro.2011.0036
66. Barreto GE, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
67. Barreto GE, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
68. Barreto GE, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
69. Barreto GE, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
70. Barreto GE, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
71. Barreto GE, Gonzalez J, Capani F, Morales L. Neuroprotective agents in brain
the upregulation of neuroglobin expression. *Mol Cell Endocrinol* (2016). doi:10.1016/j.mce.2016.05.024

66. Acaz-Fonseca E, Avila E, Rodriguez M, Garcia-Segura LM, Barreto GE. Regulation of astroglia by gonadal steroid hormones under physiological and pathological conditions. *Prog Neurobiol* (2016). doi:10.1016/j.pneurobio.2016.06.002

67. Torrente D, Avila MF, Cabezas R, Morales L, Gonzalez J, Sanudo I, et al. Paracrine factors of human mesenchymal stem cells increase wound closure and reduce reactive oxygen species production in a traumatic brain injury in vitro model. *Hum Exp Toxicol* (2014) 33(7):673–84. doi:10.1177/0960327113509659

68. Cantinieux D, Quertaimont R, Blacher S, Rossi L, Wanet T, Noël A, et al. Conditioned medium from bone marrow-derived mesenchymal stem cells improves recovery after spinal cord injury in rats: an original strategy to avoid cell transplantation. *PLoS One* (2013) 8:e69515. doi:10.1371/journal.pone.0069515

69. Jing L, He MT, Chang Y, Mehta SL, He QP, Zhang JZ, et al. Coenzyme A reduction protects astrocytes from ROS-induced damage through inhibition of mitochondria-mediated cell death pathway. *Int J Biol Sci* (2015) 11:59–66. doi:10.7150/ijbs.10174

70. Schneuer M, Flachsbarth S, Czech-Damal NU, Folkow LP, Siebert U, Burmester T. Neuroglobin of seals and whales: evidence for a divergent role in the diving brain. *Neuroscience* (2012) 223:35–44. doi:10.1016/j.neuroscience.2012.01.052

71. Van Weunen V, Van Dam D, Moens L, De Deyn PP, Dewilde S. A behavioural study of neuroglobin-overexpressing mice under normoxic and hypoxic conditions. *Biochim Biophys Acta* (2013) 1834:1764–71. doi:10.1016/j.bbabio.2013.04.015

72. Purushothaman S, Stone J. The reaction of cerebral cortex to a nearby lesion: a study of the upregulation of neuroglobin expression and proinflammatory responses during cerebral malaria. *Neuropathol Exp Neurol* (2013) 306:16–23. doi:10.14814/phy2.12284

73. Wang TH, Wu ML, Wu YH, Tsai WJ, Lin KP, Wang CL, et al. Neurotoxicity of inhaled 1-bromopropane in rats. *J Occup Health* (2014) 56(7):491–9. doi:10.1515/joh.2014.080

74. Zhao S, Yu Z, Zhao G, Xing C, Hayakawa K, Whalen MJ, et al. Neuroglobin-overexpression reduces traumatic brain lesion size in mice. *Neurosci Lett* (2013) 5:195–208. doi:10.1016/j.neulet.2014.03.012

75. Lackner P, Beer R, Heussler V, Goebel G, Rudzik D, Helbok R, et al. Behavioural and histopathological alterations in mice with cerebral malaria. *Neuropharmacology Appl Neurobiol* (2006) 32:177–88. doi:10.1111/j.1365-2990.2006.00706.x

76. Wiese L, Kurtzhalis JA, Penkowa M. Neuronal apoptosis, metallothionein expression and proinflammatory responses during cerebral malaria in mice. *Exp Neurol* (2006) 200:216–26. doi:10.1016/j.expneurol.2006.02.011

77. Gotting M, Nikimama M. More than hemoglobin – the unexpected diversity of globins in vertebrate red blood cells. *Physiol Rep* (2015) 3:e12284–12284. doi:10.14814/phy2.12284

78. Hankeln T, Ebner B, Fuchs C, Gerlach F, Haberkamp M, Laufs TL, et al. Neuroglobin and cytoglobin in search of their role in the vertebrate globin family. *J Inorg Biochem* (2005) 99:110–9. doi:10.1016/j.jinorgbio.2004.11.009

79. Hankeln T, Burmester T, Hankeln T. The amphibian globin gene repertoire as revealed by the Xenopus genome. *Cytogeten Genom Res* (2006) 112:296–306. doi:10.1159/000089884

80. Wustph S, Laufs T, Schmidt M, Burmester T, Maas U, Saaler-Reinhardt S, et al. Localization of neuroglobin protein in the mouse brain. *Neurosci Lett* (2003) 346:114–6. doi:10.1016/S0304-3940(03)00653-9

81. Simon R. Neuroglobin: neuroprotection and neurogenesis. *Neurosci Lett* (2014) 549:1–2. doi:10.1016/j.neulet.2013.05.016

82. Wang A, Yang Y, Wang H, Wang J, Hang X, Wang Z, et al. Upregulation of neuroglobin expression and changes in serum redox indices in a rat model of middle cerebral artery occlusion. *Mol Med Rep* (2015) 12:1693–8. doi:10.3892/mmr.2015.3593

83. Song X, Xu R, Xie F, Zhu H, Zhu J, Wang X. Hemin offers neuroprotection through inducing exogenous neuroglobin in focal cerebral hypoxic-ischemia in rats. *Int J Clin Exp Pathol* (2014) 7:2163–71.

84. Yu Z, Liu N, Li Y, Xu J, Wang X. Neuroglobin overexpression inhibits beta amyloid-induced apoptosis through inhibiting caspases activity by activating PI3K/Akt signaling pathway. *J Mol Neurosci* (2016) 58(1):28–38. doi:10.1007/s12031-015-0645-x

85. Reuss S, Saaler-Reinhardt S, Weich B, Wystub S, Reuss MH, Burmester T, et al. Localization of neuroglobin protein in the mouse brain. *Neurosci Lett* (2014) 586:142–8. doi:10.1016/j.neulet.2010.03.056

86. Tiso M, Tejero J, Basu S, Azarov I, Wang X, Simplaceanu V, et al. Human neuroglobin functions as a redox-regulated nitrile reductase. *J Biol Chem* (2011) 286:18277–89. doi:10.1074/jbc.M110.159541

87. Oliveira KC, da Conceição RR, Piedade GC, de Souza JS, Sato MA, de Barros Maciel RM, et al. Thyroid hormone modulates neuroglobin and cytoglobin in rat brain. *Metab Brain Dis* (2015) 30(6):1401–8. doi:10.1007/s11011-015-9718-5

88. Pickotti P, Dewilde S, Fago A, Hundahl C, De Filippis V, Moens L, et al. Unusual stability of human neuroglobin at low pH – molecular mechanisms and biological significance. *FEBS J* (2009) 276:7027–39. doi:10.1111/j.1742-4658.2009.07416.x

89. Burmester T, Hankeln T. What is the function of neuroglobin? *J Exp Biol* (2009) 212:1423–8. doi:10.1242/jeb.007009

90. Yu Z, Fan X, Lo EH, Wang X. Neuroprotective roles and mechanisms of neuroglobin. *Neurobiol Dis* (2009) 31:122–7. doi:10.1016/j.nbd.2009.09.006

91. Reuss S, Saaler-Reinhardt S, Weich B, Wustph S, Reuss MH, Burmester T, et al. Expression analysis of neuroglobin mRNA in rodent tissues. *Neuroscience* (2002) 115:645–56. doi:10.1016/S0306-4522(02)00536-5

92. Hundahl CA, Allen GC, Hannibal J, Kjaer K, Rehfeld JF, Dewilde S, et al. Anatomical characterization of cytoglobin and neuroglobin mRNA and protein expression in the mouse brain. *Brain Res* (2010) 1331:58–73. doi:10.1016/j.brainres.2010.03.056

93. Watanabe S, Takahashi N, Uchida H, Wakasagi K. Human neuroglobin functions as an oxidative stress-responsive sensor for neuroprotection. *J Biol Chem* (2012) 287:30128–38. doi:10.1074/jbc.M111.337381

94. Yu Z, Liu J, Guo S, Xing C, Fan X, Ning M, et al. Neuroglobin-overexpression alters hypoxic response gene expression in primary neuron culture following oxygen glucose deprivation. *Neuroscience* (2009) 162:396–403. doi:10.1016/j.neuroscience.2009.04.055

95. Yu Z, Liu N, Li Y, Xu J, Wang X. Neuroglobin overexpression inhibits oxygen-glucose deprivation-induced mitochondrial permeability transition pore opening in primary cultured mouse cortical neurons. *Neurobiol Dis* (2013) 56:95–103. doi:10.1016/j.nbd.2013.04.015
cells exposed to glucose deprivation. *Front Aging Neurosci* (2016) 8:152. doi:10.3389/fnagi.2016.00152

125. Avivi A, Geralch F, Joel A, Reus S, Burmester T, Nevo E, et al. Neuroglobin, cytooglobin, and myoglobin contribute to hypoxia adaptation of the subterranean mole rat Spalax. *Proc Natl Acad Sci U S A* (2010) 107:21570–5. doi:10.1073/pnas.1005791107

126. Greenberg DA, Jin K, Khan AA. Neuroglobin: an endogenous neuroprotectant. *Curr Opin Pharmacol* (2008) 8:20–4. doi:10.1016/j.coph.2007.09.003

127. Sun Y, Jin K, Peel A, Mao XO, Xie L, Greenberg DA. Neuroglobin protects the brain from experimental stroke in vivo. *Proc Natl Acad Sci U S A* (2003) 100:3497–500. doi:10.1073/pnas.0637726100

128. Fago A, Hundalh C, De Wilde S, Gilany K, Moens L, Weber RE. Allosteric regulation and temperature dependence of oxygen binding in human neuroglobin and cytooglobin. Molecular mechanisms and physiological significance. *J Biol Chem* (2004) 279:44417–26. doi:10.1074/jbc.M407126200

129. Brunori M, Giuffrè A, Nienhaus K, Nienhaus GU, Scardurra FM, Vallone B. Neuroglobin, nitric oxide, and oxygen: functional pathways and conformational changes. *Proc Natl Acad Sci U S A* (2005) 102:8483–8. doi:10.1073/pnas.0408766102

130. Jin K, Mao Y, Mao X, Xie L, Greenberg DA. Neuroglobin expression in ischemic stroke. *Stroke* (2010) 41:557–9. doi:10.1161/STROKEAHA.109.567149

131. Chen XQ, Qin LY, Zhang CG, Yang LT, Gao Z, Liu S, et al. Presence of neuroglobin in rat cultured astrocytes. *Glia* (2005) 56:182–6. doi:10.1002/glia.20147

132. Lechaume C, Augustin S, Roussel D, Sahel JA, Corral-Debrinski M. Neuroglobin involvement in visual pathways through the optic nerve. *Biochim Biophys Acta* (2013) 1834:1772–8. doi:10.1016/j.bbabio.2013.04.014

133. De Marinis E, Acaz-Fonseca E, Arevalo MA, Ascenzi P, Fiochetti M, Marino M, et al. 17beta-oestradiol anti-inflammatory effects in primary astrocytes require oestrogen receptor beta-mediated neuroglobin up-regulation. *J Neuroendocrinol* (2013) 25:260–70. doi:10.1111/jne.12007

134. DellaValle B, Hempel C, Kurtzhals JA, Penkowa M. In vivo expression of cytoglobin in solid tumours and cancer cells. *Acta Physiol (Oxf)* (2010) 201:3497–500. doi:10.1111/j.1748-1716.2010.02205.x

135. Qin H, Guo Y, Zhang C, Zhang L, Li M, Guan P. The expression of neuroglobin in astrocytoma. *Brain Tumor Pathol* (2012) 29:10–6. doi:10.1007/s10014-011-0066-9

136. Guglielmotto M, Reineri S, Lannello A, Ferrero G, Vanzan L, Miano V, et al. E2 regulates epigenetic signature on neuroglobin enhancer-promoter in neuronal cells. *Front Cell Neurosci* (2016) 10:147. doi:10.3389/fncel.2016.00147

137. Hundal CA, Fahrenkrug J, Hay-Schmidt A, Georg B, Fallof B, Hannibal J. Circadian behaviour in neuroglobin deficient mice. *PLoS One* (2012) 7:e34462. doi:10.1371/journal.pone.0034462

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.